RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Li, Jun;Liao, Dan;Wang, Fujue;Wang, Zhongwang;Li, Yueshan;...

通讯作者：

Niu, Ting

作者机构：

[Li, Jun; Niu, Ting; Wang, Zhongwang; Liao, Dan; Wang, Fujue] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China.

[Liao, Dan] Third Hosp Mianyang, Dept Hematol, Mianyang, Sichuan, Peoples R China.

[Wang, Fujue] Univ South China, Affiliated Hosp 1, Dept Hematol, Hengyang, Peoples R China.

[Li, Yueshan; Xiong, Yu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.

[Li, Yueshan; Xiong, Yu] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China.

通讯机构：

[Niu, Ting] S

Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China.

语种：

英文

关键词：

Receptor-interacting protein kinase-1;acute myeloid leukemia;FLT3-ITD;chidamide;necroptosis

期刊：

Leukemia & Lymphoma

ISSN：

1042-8194

年：

2022

卷：

期：

页码：

1167-1179

DOI：

10.1080/10428194.2021.2010056

基金类别：

National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81930125]; Incubation Program for Clinical Trials [19HXFH030]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21007]; NCRCH [2021WWB03]; Natural Science Foundation of Hunan ProvinceNatural Science Foundation of Hunan Province [2021JJ40501]

机构署名：

本校为其他机构

摘要：

Acute myeloid leukemia (AML) with FLT3-ITD mutation accounts for a large proportion of relapsed/refractory AML with poor prognosis. RIPK1 is a known key regulator of necroptosis and RIPK1 inhibition shows anti-AML effects in vitro. Chidamide is a histone deacetylase inhibitor (HDACi) with proven ability to induce apoptosis in FLT3-ITD positive AML cells. In the present study, we evaluated the effects of the combination of 22b, a novel RIPK1 inhibitor, and chidamide on proliferation and apoptosis in FLT3-ITD positive AML cell lines and primary cells. The results showed that 22b could significan...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问